12:00 AM
May 14, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Capesaris: Phase II start

FDA lifted a full clinical hold on Capesaris from GTx after reviewing the company's complete response and its new Phase II clinical protocol. Next quarter, GTx will begin an open-label Phase II trial to evaluate 3 lower doses - 125, 250 and 500 mg - of Capesaris daily in about 75 men with metastatic CRPC maintained on primary androgen deprivation therapy (ADT). In February, FDA placed a clinical hold...

Read the full 325 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >